Table 3.
Ongoing and future expected clinical trials
|
Study name, NCT number
|
Year of study start
|
Study phase
|
Cardiovascular disease
|
Number of patients
|
Type of cardiac cells
|
Route of delivery
|
| Regress-HFpEF, 02941705 | 2017 | II | Symptomatic hypertensive heart disease induced HFpEF | 40 | Allogeneic CDCs | IC |
| APOLLON trial, 02781922 | 2016 | III | HLHS | 40 | Autologous CSCs | IC |
| CHILD, 03406884 | 2019 | I | HLHS | 32 | Autologous c-KIT+ cells | IM |
| ALPHA, 03145298 | 2017 | I | PAH | 26 | Allogeneic CDC | IV |
| TAC-HFT-II, 02503280 | 2025 | I/II | IHF | 0 enrollment until now | Autologous combination of MSCs and CSCs | Trans endocardial Injection |
CSC: Cardiac stem cell; HFpEF: Heart failure with preserved ejection fraction; HLHS: Hypoplastic left heart syndrome; IC: Intracardiac; IHF: Ischemic heart failure; IM: Intramyocardial; IV: Intravenous; NCT: National clinical trial; PAH: Pulmonary atrial hypertension.